• Mashup Score: 0
    Trial of Donanemab in Early Symptomatic Alzheimer Disease - 8 month(s) ago

    This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NHLBI_Translate
      NHLBI_Translate

      .@JAMA_current: Among patients with early symptomatic #AlzheimerDisease and amyloid and tau pathology, #donanemab treatment significantly slowed clinical progression at 76 weeks. #Amyloidosis #TRAILBLAZER-ALZ 2 Randomized Clinical Trial #placebo #outcomes https://t.co/XSfu0mF0EP https://t.co/GqhwZnIQgZ

  • Mashup Score: 1
    Trial of Donanemab in Early Symptomatic Alzheimer Disease - 9 month(s) ago

    This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ProfMakris
      ProfMakris

      The adverse events of Donanemab (used for early #Alzheimer disease) seem significant. 314/853 (36.8%) of patients developed amyloid related imaging abnormality of edema or microhemorrhage and 112 discontinued treatment. https://t.co/8LKm1XLOTY #donanemab https://t.co/FlnaREgixz

  • Mashup Score: 4
    Trial of Donanemab in Early Symptomatic Alzheimer Disease - 9 month(s) ago

    This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

    Source: jamanetwork.com
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CMichaelGibson
      CMichaelGibson

      Among patients with early symptomatic #AlzheimerDisease and #amyloid and #tau pathology, #donanemab treatment significantly slowed clinical progression at 76 weeks TRAILBLAZER 2 Trial https://t.co/ewUqwm1lMR #AAIC23 https://t.co/h1LHUCCtKd

  • Mashup Score: 4
    Eli Lilly's Alzheimer's therapy slowed patients' rate of cognitive decline, data show - 12 month(s) ago

    A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, boosting hopes for a new class of Alzheimer’s drugs.

    Source: STAT
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CMichaelGibson
      CMichaelGibson

      Eli Lilly’s Alzheimer’s drug #donanemab slowed patients’ rate of cognitive and functional decline by 35% in a Phase 3 trial, but 2 patients & possibly a 3rd died from a type of brain swelling caused by the drug. @matthewherper https://t.co/BPUe8jaZir

  • Mashup Score: 1
    Wolters Kluwer Health - 2 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: lww.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of NeurologyToday
      NeurologyToday

      Via @JAMANeuro: An analysis of #aducanumab and #donanemab found that at current expected prices, neither drug would be cost-effective for the treatment of early #AlzheimersDisease in the US. https://t.co/EVkvi2oFKn @MassGeneralNews #NeuroTwitter https://t.co/Fi2BAvbdnc

  • Mashup Score: 2
    Donanemab in Early Alzheimer's Disease - PubMed - 3 year(s) ago

    In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficac …

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of pash22
      pash22

      RT @MadhavThambiset: Good surrogate @US_FDA ? #donanemab #NEJM https://t.co/qtWCx9I8T9 before #Aducanumab approval "greater reduction in a…

  • Mashup Score: 3
    Wolters Kluwer Health - 3 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…

    Source: journals.lww.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of NeurologyToday
      NeurologyToday

      Via @NEJM: #Donanemab, a monoclonal antibody that targets a unique epitope on the amyloid-beta (Abeta) peptide, cleared the sticky plaque in the brains of people in the early stages of #Alzheimersdisease.#NeuroTwitter @ApostolovaLiana @a_hfillit @samgandy https://t.co/GpCYWRLOJ3 https://t.co/VysElnsvve

Load More